5,7,8-trichloro-3,4-dihydro-2H-pyrano<3.2-c>pyridine | 81706-86-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 5,7,8-trichloro-3,4-dihydro-2H-pyrano<3.2-c>pyridine
• 英文别名: 5,7,8-trichloro-3,4-dihydro-2H-pyrano[3,2-c]pyridine
• CAS: 81706-86-7
• 化学式: C₈H₆Cl₃NO
• 分子量: 238.501
• InChiKey: XGIXFZDSJJLJMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3,5,6-四氯-4-羟基吡啶 在 18-冠醚-6 、 potassium carbonate 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 反应 36.0h， 生成 5,7,8-trichloro-3,4-dihydro-2H-pyrano<3.2-c>pyridine
  参考文献：
  名称：

  Wakefield, Basil J.; Whitten, Jeffrey P.; Farley, Paul S., Journal of the Chemical Society. Perkin transactions I, 1982, p. 93 - 100

  摘要：

  DOI：

文献信息

• Chemokine Receptor Antagonist and Medical Use Thereof
  申请人：Habashita Hiromu

  公开号：US20070254886A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

  本发明涉及一种由公式（I）表示的化合物，其盐、N-氧化物、溶剂化物或前药，以及其医药用途（公式中的符号如说明书所述）。公式（I）表示的化合物具有趋化因子受体（尤其是在CCR4和/或CCR5中）拮抗活性。因此，它对于预防和/或治疗趋化因子受体介导的疾病，如炎症和/或过敏性疾病[全身性炎症反应综合征（SIRS）、过敏性休克、过敏性反应、过敏性血管炎、移植排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼部疾病、炎症性肠病、脑和/或循环系统疾病、呼吸系统疾病、皮肤病、自身免疫性疾病等]、感染[病毒性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合征、SARS等）等]等非常有用。
• CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF
  申请人：HABASHITA Hiromu

  公开号：US20100266539A1

  公开（公告）日：2010-10-21

  The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

  本发明涉及一种由式（I）所表示的化合物，其盐、N-氧化物、溶剂化物或前药，以及其医药用途（式中符号如规范所述）。由式（I）所表示的化合物具有趋化因子受体（特别是在CCR4和/或CCR5中）的拮抗活性。因此，它对于预防和/或治疗趋化因子受体介导的疾病，如炎症和/或过敏性疾病[全身性炎症反应综合征（SIRS）、过敏反应、过敏性血管炎、移植排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼病、炎症性肠病、脑和/或循环系统疾病、呼吸道疾病、皮肤病、自身免疫性疾病等]、感染[病毒性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合征、SARS等）等]等具有用处。
• WAKEFIELD, B. J.;WHITTEN, J. P.;FARLEY, P. S., J. CHEM. SOC. PERKIN. TRANS., 1982, N 1, 93-99
  作者：WAKEFIELD, B. J.、WHITTEN, J. P.、FARLEY, P. S.

  DOI：——

  日期：——
• US7732442B2
  申请人：——

  公开号：US7732442B2

  公开（公告）日：2010-06-08
• Wakefield, Basil J.; Whitten, Jeffrey P.; Farley, Paul S., Journal of the Chemical Society. Perkin transactions I, 1982, p. 93 - 100
  作者：Wakefield, Basil J.、Whitten, Jeffrey P.、Farley, Paul S.

  DOI：——

  日期：——

表征谱图